Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Oncology Drugs in Phase III Clinical Development in FINLAND

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Orion Corporation

              • Development Update

              Virtual BoothBegin the journey of your innovative API with Fermion.

              FINLAND Finland

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              ARAMIS Phase III Data to be Presented at ASCO 2020 Reveals Nubeqa Linked with Improved Overall Survival in Non-Metastatic Prostate Cancer

              Contact the Supplier

              Lead Product(s): Darolutamide

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 14, 2020

              Details:

              Darolutamide significantly reduced risk of death by 31 percent in men with non-metastatic castration-resistant prostate cancer (nmCRPC).

              Orion Corporation

              • Development Update

              Virtual BoothBegin the journey of your innovative API with Fermion.

              FINLAND Finland

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              Virtual Innovation Day

              Participation Not Confirmed

              Update your events

              Positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer

              Contact the Supplier

              Lead Product(s): Darolutamide

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 31, 2020

              Details:

              The CHMP recommendation is based on the results of the Phase III ARAMIS trial evaluating darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT.

              PharmaCompass__DigitalAd